Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 2
2017 1
2018 3
2019 3
2021 3
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Results by year
Filters applied: . Clear all
Page 1
Causes of death and comorbidities in hospitalized patients with COVID-19.
Elezkurtaj S, Greuel S, Ihlow J, Michaelis EG, Bischoff P, Kunze CA, Sinn BV, Gerhold M, Hauptmann K, Ingold-Heppner B, Miller F, Herbst H, Corman VM, Martin H, Radbruch H, Heppner FL, Horst D. Elezkurtaj S, et al. Among authors: kunze ca. Sci Rep. 2021 Feb 19;11(1):4263. doi: 10.1038/s41598-021-82862-5. Sci Rep. 2021. PMID: 33608563 Free PMC article.
COVID-19: Autopsy findings in six patients between 26 and 46 years of age.
Greuel S, Ihlow J, Dragomir MP, Streit S, Corman VM, Haberbosch L, Winkler D, Meinhardt J, Aschman T, Schneider J, Trotsyuk I, Kunze CA, Maurer L, Radbruch H, Heppner FL, Horst D, Elezkurtaj S. Greuel S, et al. Among authors: kunze ca. Int J Infect Dis. 2021 Jul;108:274-281. doi: 10.1016/j.ijid.2021.05.069. Epub 2021 Jun 3. Int J Infect Dis. 2021. PMID: 34089883 Free PMC article.
Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial.
Coombes RC, Tovey H, Kilburn L, Mansi J, Palmieri C, Bartlett J, Hicks J, Makris A, Evans A, Loibl S, Denkert C, Murray E, Grieve R, Coleman R, Borley A, Schmidt M, Rautenberg B, Kunze CA, Rhein U, Mehta K, Mousa K, Dibble T, Lu XL, von Minckwitz G, Bliss JM; Randomized European Celecoxib Trial (REACT) Trial Management Group and Investigators. Coombes RC, et al. Among authors: kunze ca. JAMA Oncol. 2021 Sep 1;7(9):1291-1301. doi: 10.1001/jamaoncol.2021.2193. JAMA Oncol. 2021. PMID: 34264305 Free PMC article. Clinical Trial.
MALDI-Imaging for Classification of Epithelial Ovarian Cancer Histotypes from a Tissue Microarray Using Machine Learning Methods.
Klein O, Kanter F, Kulbe H, Jank P, Denkert C, Nebrich G, Schmitt WD, Wu Z, Kunze CA, Sehouli J, Darb-Esfahani S, Braicu I, Lellmann J, Thiele H, Taube ET. Klein O, et al. Among authors: kunze ca. Proteomics Clin Appl. 2019 Jan;13(1):e1700181. doi: 10.1002/prca.201700181. Epub 2018 Dec 14. Proteomics Clin Appl. 2019. PMID: 30471200
Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network.
Sehouli J, Braicu EI, Richter R, Denkert C, Jank P, Jurmeister PS, Kunze CA, Budczies J, Darb-Esfahani S, Schmitt WD, Traut A, Grabowski J, Taube ET, Plett H. Sehouli J, et al. Among authors: kunze ca. Hum Pathol. 2019 Mar;85:299-308. doi: 10.1016/j.humpath.2018.10.020. Epub 2018 Nov 11. Hum Pathol. 2019. PMID: 30428389
Prognostic value of regulatory T cells and T helper 17 cells in high grade serous ovarian carcinoma.
Marchenko S, Piwonski I, Hoffmann I, Sinn BV, Kunze CA, Monjé N, Pohl J, Kulbe H, Schmitt WD, Darb-Esfahani S, Braicu EI, von Brünneck AC, Sehouli J, Denkert C, Horst D, Jöhrens K, Taube ET. Marchenko S, et al. Among authors: kunze ca. J Cancer Res Clin Oncol. 2022 Jun 28. doi: 10.1007/s00432-022-04101-2. Online ahead of print. J Cancer Res Clin Oncol. 2022. PMID: 35763108
Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Darb-Esfahani S, Kunze CA, Kulbe H, Sehouli J, Wienert S, Lindner J, Budczies J, Bockmayr M, Dietel M, Denkert C, Braicu I, Jöhrens K. Darb-Esfahani S, et al. Among authors: kunze ca. Oncotarget. 2016 Jan 12;7(2):1486-99. doi: 10.18632/oncotarget.6429. Oncotarget. 2016. PMID: 26625204 Free PMC article.